BillionToOne, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
BillionToOne reported Q2 2026 total revenue of $109.4M (vs. $66.6M in Q2 2025), a 64% increase driven by 35% growth in tests delivered (196,000 tests) and 21% ASP increase to $551/test. Prenatal revenue grew 55% to $94.2M; oncology surged 176% to $13.7M. The company achieved operating income of $5.5M (vs. $1.6M operating loss in Q2 2025), gross margin improved 5 percentage points to 70%, and net income was $8.1M ($0.15 diluted EPS). Management reiterated full-year 2026 guidance of $450–465M revenue (48–52% growth) and expects to maintain profitability with continued investment. Free cash flow was positive at $5.1M in Q2.
Why this rating
Strong 64% YoY revenue growth with operating profitability inflection is meaningful; Q2 revenue ~15% of trailing 12-month run-rate ($438M annualized). Oncology 176% growth and margin expansion are positive. Guidance reiteration and positive FCF support trajectory. Relative to $700.7M asset base, this is material but not transformational.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.